By analysing those clinical data from medicine trials, we found that blocking bioactivity of IGF1R or IGF ligands using antibody was not appropriate because antibodies could not eliminate the overexpression of IGF on the surface of tumour cells. This evidence concerns the gene IGF1R and neoplasm.